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PURPOSES: To evaluate whether sublobar resections afforded recurrence and survival rates 
equivalent to lobectomy in high-risk elderly patients.   
METHODS: This is a retrospective multicenter study including all consecutive patients aged > 
75 years operated for Clinical Stage I Non Small Cell Lung Cancer. Clinico-pathological data, 
postoperative morbidity and mortality, recurrence rate and vital status were retrieved. Overall survival, 
cancer specific survival and disease-free survival were assessed.   
RESULTS: 239 patients (median age: 78 years) were enrolled. Lobectomies were performed in 
149 (62.3%) patients, sublobar resections in 90 (39 segmentectomies, 51 wedge resections). The 
recurrence rate following lobar versus sublobar resections showed no significant difference (19% 
versus 23% respectively, p=0.5), as well as overall survival (p=0.1), cancer specific survival (p=0.3) 
and disease-free survival (p=0.1). Even after adjusting for 1:1 propensity-matching score and matched 
pair analysis, results were unchanged. Tumor size > 2 cm and pN2 disease were  independent negative 
prognostic factors in unmatched (p=0.01 and p=0.0003 respectively) and matched (p=0.02 and p=0.005 
respectively) analysis.    
CONCLUSIONS: High-risk elderly patients may benefit from sublobar resections which 




Surgical resection constitutes the most effective treatment for early-stage non-small cell lung 
cancer (NSCLC). In recent years, computed tomography screening has allowed diagnosing 
approximately 25-30% of NSCLCs at an early stage and it is expected that this incidence will increase 
in the future [1].   
Despite some authors [2,3,4,5] supported the hypothesis that in selected patients with clinical 
Stage I  T1aN0M0 NSCLC sublobar resection produces similar survival rates compared to greater 
resection, lobectomy remains the approach of choice as stated several years ago by the only existing 
randomized controlled trial from the Lung Cancer Study Group [6]. This observation was also recently 
confirmed by Whitson et al. [7] who evaluated 14.473 patients with clinical Stage I NSCLC from the 
Surveillance Epidemiology and End Results (SEER) register and found that lobectomy had conferred 
superior overall 5-year survival (p<0.0001) and 5-year cancer-specific survival (p=0.0053) rates over 
segmental resection. Two multicentre, prospective, randomized studies focused on this topic 
(lobectomy versus sublobar resection) are currently under way (Cancer and Leukemia Group B 
140503; Japanese Clinical Oncology Group 0802/West Japan Oncology Group 4607L) but the data 
have not been published yet and will help define the role of sublobar resection in the treatment of 
NSCLC patients.  
However, a considerable number of elderly patients with early-stage NSCLC are unfit for 
lobectomy due to poor cardiopulmonary reserve and multiple comorbidities.  Thus, in such cases 
sublobar resection may be indicated as an alternative to lobectomy in order to reduce the perioperative 
morbidity and mortality, at the price of questionable oncologic validity. 
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The aim of the present study was to evaluate if sub-lobar resection (SLR) was a reasonable 
alternative to lobar resection (LR) in terms of survival in high-risk, elderly patients with Stage I  
NSCLC.  
 
MATERIAL AND METHODS 
Study Design 
 This is a retrospective multicenter study including all consecutive patients aged over 75 years-
old, with Clinical Stage T1a,b-2aN0 (Stage I) NSCLC as determined by positron emission 
tomography/computed tomography (PET/CT) scan, and undergoing LR or SLR from January 2006 to 
December 2012. Patients with (i) a final histological diagnosis different from NSCLC (i.e. small cell 
lung cancer; carcinoid tumor etc…); (ii) neoadjuvant therapy; and (iii) radiologically non-solid tumor 
as pure ground glass opacity (GGO) or mixed GGO were excluded. SLR was considered as primary 
resection therapy for patients with peripheral lung cancer and significant cardiopulmonary impairment 
or important co-morbidity. In all other cases, a LR was performed.  
The two study groups (SLR versus LR) were statistically compared to assess any differences in 
recurrence, overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS).  To 
avoid difference bias due to the retrospective nature of the study, LR patients were then chosen with the 
highest concordance with SLR patients using propensity score matching analysis and the different 
outcome between the new two groups was re-analyzed.  
The data and variables were collected retrospectively from structured lung cancer databases of 
each participating center. Chart review was used as necessary to complete data collection.  A written 
signed consent was obtained by patients for entry into database according to the policy of each 
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participating center and patients were aware that these data would be used for research purpose. Ethical 





254 patients were eligible for the present study. All patients were clinically staged by PET/CT 
scan.   In cases with a positive PET/CT scan (N2 or M1), additional diagnostic testing was carried out 
for confirmation purposes. If bone or brain were suspected to harbor metastases, magnetic resonance 
imaging (MRI) was considered as the standard reference. Pulmonary function was evaluated with 
spirometry and lung carbon monoxide diffusion testing (DLCO). Preoperative cardiac function 
evaluation was routinely performed by echocardiography with left ejection fraction (EF) and 
pulmonary artery pressure (PAP) estimate and treadmill stress test; occasionally, the quantitative V/Q 
scan and cardiopulmonary stress test were required for borderline patients to assess oxygen 
consumption and pulmonary function. The histological diagnosis of the tumor was obtained whenever 
possible preoperatively with transparietal CT guided-biopsy and/or bronchoscopy or on the resected 
specimen at on-site analysis at surgery.  
The type of resection was categorized in two groups according to the extent of pulmonary 
resection. LR group included standard lobectomy while SLR counted segmentectomy and wedge 
resection. Patients were considered unfit for lobectomy and scheduled for sublobar resection in 
presence of major cardiovascular, respiratory and other heavy significant co-morbidity conditions. 
Hilar and mediastinal lymph nodes (LN) were sampled or systematically dissected during lobectomy or 
segmentectomy to evaluate for the possibility of occult lymph node involvement. On the other hand, 
only enlarged nodes were sampled in patients undergoing wedge resection.  
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Hospital and office records of each patient were reviewed for demographic, clinical and 
pathological data, including gender, smoking status, co-morbidities stratified according Charlson Co-
Morbidity Index, clinical and pathological stage, according to the seventh edition of TNM. Operative 
mortality was defined as any death within 30 days of operation or prior to dismissal. Complications 
were classified as major (potentially life-threatening) including pneumonia, myocardial infarction, 
stroke, bleeding, adult respiratory failure, and need for re-intubation occurring within 30 days of 
surgery, or within 3 months in case of empyema or bronchopleural fistula; and as minor (non-life-
threatening, requiring medical therapy and/or prolonged hospital stay.   
Survival    
End points of the analysis included recurrence pattern (locoregional or distant), OS, CSS, and 
DFS.  Loco-regional recurrence was defined as any recurrence within the same lobe of the lung, or 
interlobar and hilar lymph nodes. All other relapses were classified as distant recurrence. OS was 
measured from the date of surgery until death. In addition, patients without event was censored at the 
time of last follow up. CSS was measured from the date of surgery to the date of death related to lung 
cancer. DFS was calculated from the date of surgery until any loco regional, or distant disease 
recurrence occurred, or until last follow-up.   
Statistical Analysis.  
The summary statistics of patient's characteristics were tabulated either as number of patients 
(N), mean ± standard deviation (SD), for continuous variables or as number of patients and percentages 
for categorical variables.  Student's t-test and chi-square test were used to compare different variables, 
as appropriate. Survival was calculated by the Kaplan-Meier method and difference assessed by log-
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rank test.  A multivariable analysis for prognostic factors was performed using the Cox proportional-
hazards regression model.  
To control the differences in prognostic and stratification factors between the study groups, we 
created a propensity score matched pairs without replacement (1:1). The following covariates were 
used for propensity score matching analysis: ppoFEV1 % (≤40% or >40%); ppoDLCO % (≤40% or 
>40%);  heart cardiac failure (yes or no);  pT (≤20 mm or >20 mm);  pN2 disease (yes or no);  major 
post-operative complications (yes or no). Specifically, we sought to match each lobar patient to a 
sublobar patient who had a propensity score that was identical to 6 digits. If this match could not be 
found, the algorithm then proceeded sequentially to the next highest digit match (a 5-; 4-; 3- or 1- digit) 
on propensity score to make "next best" matches, in a hierarchical sequence until no more matches 
could be made. Once a match was made, previous matches were not reconsidered before making the 
next match.  
A p < 0.05 was considered significant. MedCalc statistical software (Version 12.3, Broekstraat 
52; 9030 Mariakerke; Belgium) and STATA version 11.0 (College Station, TX) were used for analysis.   
 
RESULTS 
Among 254 eligible patients, 15/254 (6%) were excluded because of final histological diagnosis 
different from NSCLC (2 small cell lung cancers and 4 carcinoid tumors); neodjuvant therapy (n=1); 
and non-solid tumor (n=8). Thus, our study population included 239 patients (median age: 78 years).  
LR was performed in 149 (62.3%) patients while SLRs in 90 (39 segmentectomies, 51 wedge 
resections) cases. The flow chart of the study is shown in Figure 1.   
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The characteristics of the two study groups are reported in Table 1. There were no significant 
differences in age, gender, clinical and pathological tumor size, or histology when the SLR and LR 
cohorts were compared. On the other hand, compared to patients undergoing LR, patients undergoing 
SLR showed significantly worse preoperative and predicted postoperative pulmonary function, 
impaired cardiac status, and higher Charlson comorbidity index. In the SLR group, 11 wedge resections 
were performed using Video-Assisted Thoracic Surgery (VATS) while only one VATS procedure was 
carried out in the LR group (p=0.0003).  Fewer mediastinal LN stations were sampled during sublobar 
resection compared with lobar resection (p=0.0001) as well as during wedge resection compared with 
segmentectomy (p=0.01).  The pathological tumor size was similar in the study groups.  Major (p=0.4) 
and minor (p=0.2) complications were not correlated with the extent of resection.  One patient 
undergoing LR died within 30 days of operation due to respiratory failure. 
Recurrence  
The incidence and distribution of recurrences are summarized in Table 2. The recurrence rate 
following LR versus SLR showed no significant difference (19% versus 23%; respectively, p=0.5). 
However, patients who underwent SLR had a significantly higher local recurrence rate than patients 
undergoing LR (13% versus 2%; p=0.0005). In the SLR group, local recurrences were significantly 
fewer after segmentectomy compared to wedge resection (3% versus 21%; respectively, p=0.03) while 
no significant differences were found when considering overall (26% versus 19%; respectively, p=0.5) 
and distant recurrence rates (5% versus 16%; respectively, p=0.1).  Following local recurrence, 3 out of 
3 patients in the LR group and 10 out of 12 patients in the SLR group underwent radiation therapy 
while, following distant recurrence, only 14 (54%) out of 26 patients in the LR group and 2 (22%) out 




In LR group, 50/149 (34%) patients died; 23/50 (46%) for cancer-related cause and 27/50 
(54%) for not-cancer related causes including respiratory failure (n=9/27; 33%), heart failure (6/27; 
22%); acute myocardial infarction (n=5/27; 19%); and cerebrovascular accident (n=7/27; 26%). The 
remaining  99/149 (66%) were alive with stable disease status (n=6/99; 6%) or no evidence of disease 
(93/99;94%).   
In SLR group, 30/90 (33%) LR patients died;  11/30 (37%) for cancer-related cause and 19/30 
(63%) for not-cancer related causes including respiratory failure (n=2/19; 11%), heart failure (7/19; 
37%); acute myocardial infarction (n=4/19; 21%), cerebrovascular accident (n=5/19; 26%), and kidney 
failure (1/19; 5%). The remaining  60/90 (67%) were alive with stable disease status (n=10/60; 17%) or 
no evidence of disease (50/60;83%).   
Overall Survival.  The unmatched 5-year OS (Figure 2/A) was 60.5% in LR group and 45% in 
SLR group. Despite LR group presented a better trend compared to SLR group, the difference was not 
significant (Hazard Ratio (HR): 0.7; 95% Confidence Interval (CI): 0.45-1.17; p=0.1).  The matched 5-
year OS of LR and SLR group was 58% and 41%, respectively (HR=0.7; 95% CI: 0.44-1.22; p=0.2; 
Figure 3/A). No significant difference in OS was found between different types of resection after 
unmatched (p=0.1, Figure 4/A) and matched analysis  (p=0.4; Figure 5/A). 
Cancer Specific Survival.  The unmatched 5-year CSS was 71% in LR group and 59% in SLR 
group. Despite SLR group presented a worse trend compared to LR group, the difference was not 
significant (HR: 0.7; 95% CI: 0.39-1.437; p=0.3; Figure 2/B). The matched 5-year CSS of LR and SLR 
group was 69% and 62%, respectively (HR: 0.6; 95% CI: 0.32-1.17; p=0.6, Figure 3/B). The 
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comparison of different types of resection showed no significant difference in unmatched CSS (p=0.5, 
Figure 4/B)  and matched CSS (p=0.1, Figure 5/B), respectively.   
Disease Free Survival. The unmatched 5-year DFS was 60% in SL group and 36% in SLR 
group (HR: 0.7; 95% CI: 0.44-1.16; p=0.1, Figure 2/C). The matched 5-year DFS was 59% in SL group 
and 38% in SLR group (HR=0.7; 95% CI: 0.43-1.22; p=0.2, Figure 3/C). Also the comparison of 
different types of resection showed no significant difference after unmatched (p=0.1, Figure 4/C) and 
matched (p=0.4, Figure 5/C) analysis.     
Cox regression analysis 
The results were summarized in Table 3. Tumor size > 2 cm (HR= 2.8; 95% CI: 0.65-3.48; 
p=0.01) and pN2 disease (HR= 3.4; 95% CI: 0.27-4.87; p=0.0003) were independent negative 
prognostic factors of overall survival in unmatched analysis and matched analysis (pT> 2cm: HR= 2.7; 




The increasing age among the general population, improvements in imaging technology, and 
the use of CT scan in screening programs have produced larger numbers of elderly patients referring to 
their physicians with localized, early-stage NSCLC. LR is the standard of care for resection of NSCLC 
but it may not be so well defined for the elderly as it is for the younger counterpart.  
When treating elderly patients, resection planning (LR or SLR) must carefully balance the risks 
of postsurgical morbidity and mortality against those affecting cancer recurrence and long-term 
survival. There are many elderly patients with poor preoperative functional reserve and increased 
comorbidity for whom LR is not recommended but that could benefit from a SLR that minimizes 
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perioperative morbidity and mortality with a small decrement, if any, in long term-survival due to 
limited life expectancy. In fact, if left untreated, these patients die of their malignancy rather of age 
and/or comorbidities.  
Having in mind such hypothesis, we evaluated in a multicenter retrospective study the impact of 
the extent of resection (LR versus SLR) on recurrence rate and pattern and as well as on long-term 
survival of elderly patients with Stage I NSCLC. The issue is still controversial due to the paucity of 
data in literature, most likely because older patients tend to be poorly represented in cancer treatment 
trials, and generally undergo fewer diagnostic and therapeutic procedures than younger patients [8].  
The period following January 2006 was chosen for our analysis as during this time CT-PET 
scan was routinely performed in all participating centers for preoperative staging. Patients undergoing 
pneumonectomy were excluded since pneumonectomy is a well-known negative predictive factor of 
morbidity and mortality in elderly patients [9]. In addition, patients with a final histological diagnosis 
different from NSCLC (i.e. patients with small cell lung cancer or carcinoid tumor) and patients with 
radiologically non-solid nodules (i.e. GGO or mixed GGO) were excluded due to the different biologic 
behavior of these tumors.   
Our study showed that LR did not confer a significant survival advantage over SLR. Similarly, 
Okami et al [10] in a retrospective review of 133 elderly (≥75 years) patients undergoing LR (n=79) 
and SLR (n=54) showed no substantial difference in the 5-year survival rate (67.6% and 74.3%; 
p=0.92). Mery et al. [11] using the SEER database found that among patients who were ≥ 75 years of 
age LR and SLR provided similar median survival  (44 versus 42 months, respectively, p=0.47) but that 
there was a significant difference in survival in the younger subjects (both less than 65 and between 65 
and 74 years of age). Dell'Amore [12] et al as well as Okami et al [13] confirmed that lobar vs. 
sublobar resection did not confer any survival benefit in octogenarian patients with c-Stage I NSCLC. 
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Despite the incidence of recurrence was similar for the two study groups, the pattern of 
recurrence was significantly different because locoregional recurrences were more frequent in SLR 
than in LR group. Similarly, Dell'Amore et al [12] found a 9% rate of local recurrence after LR and of 
29% after SLR (p=0.001). Okami et al. [10] reported a higher incidence of local recurrence following 
sublobar rather than lobar resection in patients aged ≥ 75 years old. Since in all our cases SLRs had a 
radical intent with a 2 cm of normal lung margin, the suboptimal extent of pulmonary and mediastinal 
LN dissection might explain the higher incidence of locoregional recurrence seen in our SLR group 
compared to the LR group.   
Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that at least 
three different N2 stations should be sampled during lung cancer resection, but these goals were not 
routinely achieved, especially in the SLR group.  In only 53% (48/90) of SLR patients three or more 
different N2 stations were sampled compared to 80% (119/149) in LR group. The less accurate 
mediastinal staging could also explain the significantly lower incidence of pN2 upstaging in SLR 
compared to LR group (3% versus 13%; p=0.01). Interestingly, segmentectomy compared to wedge 
resection had a higher incidence of LN stations sampled (62% versus 38%, respectively; p=0.01) and a 
loser incidence of local locoregional recurrence  (3% versus 21%, respectively; p=0.03). Similarly, 
Landreneau et al [14] found that segmentectomy had a reduced risk of locoregional recurrence 
compared with wedge resection and that anatomic segmentectomy more closely approximated the 
oncologic results of lobectomy. Sienel et al [15] in a retrospective study of 87 patients with Stage I 
NSCLC unfit for lobectomy, found a lower rate of local recurrence (p=0.001) among patients who had 
segmentectomy, compared to patients undergoing wedge resection. Wolf et al [16] showed that patients 
undergoing SLR with LN sampled (n=45, 29%) had a local recurrence rate similar to that of patients 
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undergoing LR, while SLR patients without LNs sampled (n=109, 71%) had a local recurrence rate 
more than double compared to LR patients (p=0.0594).  
The multicenter and retrospective nature of this study reduces the possibility to evaluate the 
individual surgeon’s decision and/or patient-related factors that may impact on the choice of 
performing or not an accurate mediastinal staging. The dissection along the segmental bronchus that is 
required for segmentectomy allows removal of adjacent hilar and mediastinal lymphatic drainage, 
which might explain the higher number of N2 lymph node stations resected during segmentectomy, 
compared to wedge resection. On the other hand, pre-operative clinical conditions may influence the     
decision to perform or not an accurate mediastinal LN resection. Most likely, patients undergoing 
complete LN staging were those with better medical condition and thus scheduled for lobectomy or an 
anatomic sublobar resection. Conversely, patients with poor clinical status were more likely to be 
scheduled for wedge resection and an accurate sampling or resection of mediastinal LNs was avoided 
in order to minimize perioperative morbidity and mortality.      
However, these findings have been replicated in a number of large surgical series.  El-Sherif et 
al [17] reported that more than half of lobectomy patients had an extensive nodes dissection, whereas 
only 20% of sublobar resection patients underwent adequate LN sampling (p<0.0001). Altorki et al. 
[18] in a recent multicenter study of the International Early Lung Cancer Action Program reported that 
21% and 43% of patients undergoing LR and SLR, respectively, did not have any mediastinal LNs 
sampled. However, the 2 groups experienced similar long-term survival. Wolf et al. [15] found that, 
compared to patients who underwent lobectomy, patients undergoing sublobar resection were 
significantly less likely to have LN sampling at surgery (94% and 29%, respectively; p<0.0001). 
Finally, according to Kent et al. [19], 28% of patients having wedge resection had no LNs sampled.    
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The number of LNs and mediastinal LN stations sampled at the time of surgery improves the 
accuracy of pathologic staging, avoids misclassification of patients, and more adequately identifies 
which patients should be treated with adjuvant therapy. Indeed, our data confirm that pN2 was an 
independent negative predictor of survival.  Although patients undergoing LR had more accurate 
mediastinal staging than patients undergoing SLR, long-term survival was not statistically different 
between the 2 groups. As a matter of fact, only 3 out of 12 pN2 patients in the LR group received 
adjuvant chemotherapy while the 9 remaining patients were deemed to be unfit for adjuvant treatment 
due to presence of comorbidity, the refusal of treatment by the family or the patient, or the subjective 
and sometimes unconscious perception of frailty by the physician or the family.  On the other hand, 10 
out of 12 (83%) SLR patients with local recurrence received radiotherapy following locoregional 
recurrence. This might explain why locoregional recurrence was not significantly associated with 
decreased survival.  
Such finding was confirmed when comparing long-term survival between groups. The CSS 
curves of LR and SLR patients are much closer than those observed for OS, confirming the impression 
that most of the patients die for their pre-operative clinical conditions rather than for cancer. In 
addition, the life expectancy of 75 years old in Italy is about 87.8 years. The mean age of our SLR 
population is of 79.2 ± 3.1 and the 5-year OS after SLR was 45% and 41% in unmatched and matched 
groups, respectively. Despite the questionable oncological validity, sublobar resection seems to confer 
a survival advantage since more than 40% of our elderly population has a normal life expectancy.  
In SLR group, 63% (57/90) of cancers were adenocarcinoma but only 1/57 (2%) had a lepidic 
pattern while the remaining 56/57 (98%) had a solid growth probably because we included in our 
analysis only patients with radiologically solid tumor but excluded GGO or mixed GGO lesions. 
Theoretically,  additional survival advantage should be expected in elderly population having  GGO 
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lesions and undergoing sublobar resection. Evidences are accumulating that sublobar resections 
(segmentectomy or big wedge resection)  are oncologically equivalent to standard lobectomy  for small 
(≤2 cm) less invasive histology (Adenocarcinoma in situ or Minimal Invasive Adenocarcinoma) 
appearing as GGO on CT scan [20,21,22,23].  
Nakayama et al. [24] studied sublobar resections (49 wedge resections, 14-segmentectomy) for 
63 cT1N0M0 adenocarcinomas ≤2 cm in size. Overall survival was 95% for GGO and 69% for solid 
lesions, while recurrence-free survival was 100% in the former versus 57% in the latter.  
 
Fang et al. [20]  in a retrospective multicenter study including 173 segmentectomy patients and 
181 patients with wedge resection found that OS, CSS, and  local recurrence rates were similar between 
the two groups. Lung CSS rate at 10 years was significantly better in patients with GGO than in those 
with solid tumors (98.2% vs. 85.1%, P<0.0001). In multivariate Cox regression analysis, GGO was 
identified as an independent prognostic factor, while extent of resection had no impact on survival.  
          
In agreement with other reports [25,26,27], tumor size was confirmed as independent prognostic 
factor in the multivariable analysis. Tumors smaller than 2 cm in diameter have a more favorable 
biology. Long-term survival was significantly worse for tumors larger than 3 cm. Port et al found that 
tumor size of ≤2 cm had a better 5-year overall survival than tumor size > 2cm (77.2% versus 60.3%; 
p=0.03) [20]. Similarly, Port et al [21] found that the 5-year survival rate in patients with tumors 2 cm 
or less in diameter was 77.2% as compared with 60.3% for those with larger tumors (p=0.03). Okada et 
al [22] in a retrospective study including 1.272 patients showed that a 10-mm increase in tumor size 
was significantly associated with reduced survival.   
Finally, our data reveal that patients undergoing SLR had a significantly worse 
cardiorespiratory function and a higher Charlson comorbidity index, as compared with patients who 
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underwent LR. However, there were no significant differences in postoperative morbidity and mortality 
between the 2 groups. Most likely, the limited resection and further preservation of lung volume 
contributed to limit postoperative complications and deaths. 
Study Limitations 
Our study presents several limitations, as follows. 
First, despite all patients had a standard pre-operative evaluation, surgical treatment and follow-
up, there are differences among participating centers about clinical, pathological information data and 
treatment strategy.   
Second, due to the retrospective nature of the study, the patients were not randomly allocated to 
receive LR or SLR but this choice and surgical technique were influenced by the surgeons and each 
institution's preference and experience.  Even though we used a propensity score method to balance the 
distribution of measured confounders, observational data do not provide the same level of evidence as a 
prospective trial. In addition, residual confounding due to unconsidered covariates may remain. In 
particular, despite all resection margins included at least 2 cm of normal lung and were negative for 
tumor (R0 resection), we have no data on the exact distance from tumor to resection margin or the ratio 
between tumor size and resection margin. In addition, no data on the total number of sampled LNs was 
available.   
 
CONCLUSIONS 
Our data show that elderly patients, in poor general condition, with Stage I NSCLC may benefit 
from SLR, which is associated with similar rates of complications and perioperative mortality, when 
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compared to LR. Furthermore, although the rate of locoregional recurrence was significantly higher in 
the patients who received SLR than in  LR cases, long-term survival was equivalent between the 2 
groups. Further investigation is warranted to definitely elucidate the role of SLR in high-risk, elderly 
patients with Stage I NSCLC.          
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Figure 1. Flow chart of study population  
 
Figure 2. The comparison of between Lobar and Sublobar groups showed no significant differences in 
unmatched overall survival (p=0.1; Part A); cancer specific survival (p=0.3; Part B); and disease free 
survival (p=0.1; Part C).    
 
Figure 3. The comparison of Lobectomy, Segmentectomy and Wedge resections showed no significant 
differences in matched overall survival (p=0.2; Part A); cancer specific survival (p=0.6; Part B); and 
disease free survival (p=0.2; Part C).    
 
Figure 4. The comparison between different resections showed no significant differences in unmatched 
overall survival (p=0.1; Part A); cancer specific survival (p=0.5; Part B); and disease free survival 
(p=0.1; Part C).    
 
Figure 5. The comparison of Lobectomy, Segmentectomy and Wedge resections showed no significant 
differences in matched overall survival (p=0.4; Part A); cancer specific survival (p=0.1; Part B); and 
disease free survival (p=0.4; Part C).    
